Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheng Hu

Showing results (1291-1300 of 1,327) with videos related to

Pageof 133
Sort By:
Journal of Experimental & Clinical Cancer Research : CR|February 6, 2019
Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traitsJiaojiao Hao, Wenhua Fan, Yizhuo Li, et al.
Journal of Geriatric Cardiology : JGC|March 14, 2020
Beneficial effects of moderate to vigorous physical activity on cardiovascular disease among Chinese adultsQiong Liu, Fang-Chao Liu, Ke-Yong Huang, et al.
Journal of Geriatric Cardiology : JGC|April 28, 2021
Effects of the total physical activity and its changes on incidence, progression, and remission of hypertensionCan Cai, Fang-Chao Liu, Jian-Xin Li, et al.
Cell Reports|June 23, 2021
DDB1 binds histone reader BRWD3 to activate the transcriptional cascade in adipogenesis and promote onset of obesityXu Wang, Hao-Yan Wang, Guo-Sheng Hu, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|March 7, 2025
Artesunate attenuates skin hypertrophic scar formation by inhibiting fibroblast activation and EndMT of vascular endothelial cellsRuo-Yu Shang, Jia-Cai Yang, Wen-Gang Hu, et al.
Signal Transduction and Targeted Therapy|July 27, 2025
Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRAS<sup>G12C</sup> inhibitor-naïve Chinese patients with KRAS<sup>G12C</sup>-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studiesYing Yuan, Yanhong Deng, Yongdong Jin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I studyQing Zhou, Nong Yang, Mingfang Zhao, et al.
The Lancet. Oncology|February 28, 2025
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm studyZiming Li, Yan Wang, Yuping Sun, et al.
The Lancet. Oncology|May 11, 2025
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trialJian Zhou, Li Bai, Jia Luo, et al.
Journal of the American Chemical Society|July 28, 2012
Phase transformation and lithiation effect on electronic structure of Li(x)FePO4: an in-depth study by soft X-ray and simulationsXiaosong Liu, Jun Liu, Ruimin Qiao, et al.
Pageof 133

Showing results (1291-1300 of 1,327) with videos related to

Sort By:
Pageof 133
Journal of Experimental & Clinical Cancer Research : CR|February 6, 2019
Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traitsJiaojiao Hao, Wenhua Fan, Yizhuo Li, et al.
Journal of Geriatric Cardiology : JGC|March 14, 2020
Beneficial effects of moderate to vigorous physical activity on cardiovascular disease among Chinese adultsQiong Liu, Fang-Chao Liu, Ke-Yong Huang, et al.
Journal of Geriatric Cardiology : JGC|April 28, 2021
Effects of the total physical activity and its changes on incidence, progression, and remission of hypertensionCan Cai, Fang-Chao Liu, Jian-Xin Li, et al.
Cell Reports|June 23, 2021
DDB1 binds histone reader BRWD3 to activate the transcriptional cascade in adipogenesis and promote onset of obesityXu Wang, Hao-Yan Wang, Guo-Sheng Hu, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|March 7, 2025
Artesunate attenuates skin hypertrophic scar formation by inhibiting fibroblast activation and EndMT of vascular endothelial cellsRuo-Yu Shang, Jia-Cai Yang, Wen-Gang Hu, et al.
Signal Transduction and Targeted Therapy|July 27, 2025
Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRAS<sup>G12C</sup> inhibitor-naïve Chinese patients with KRAS<sup>G12C</sup>-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studiesYing Yuan, Yanhong Deng, Yongdong Jin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2024
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I studyQing Zhou, Nong Yang, Mingfang Zhao, et al.
The Lancet. Oncology|February 28, 2025
Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm studyZiming Li, Yan Wang, Yuping Sun, et al.
The Lancet. Oncology|May 11, 2025
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trialJian Zhou, Li Bai, Jia Luo, et al.
Journal of the American Chemical Society|July 28, 2012
Phase transformation and lithiation effect on electronic structure of Li(x)FePO4: an in-depth study by soft X-ray and simulationsXiaosong Liu, Jun Liu, Ruimin Qiao, et al.
Pageof 133